Physician profile
Susan E Albert
NPI 1982287017
$3,673.02
in general payments reported to CMS, 2019-2025
37 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.00 · 2022: $522 · 2023: $593 · 2024: $1,292 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $810.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $461.24 | 2022-2025 | |
| Glaxosmithkline, LLC. | $274.96 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $243.67 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Shield Therapeutics INC | $218.16 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $132.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $130.15 | 2021-2025 | Fanapt, Hetlioz |
| Dexcom, INC. | $124.61 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $109.66 | 2023-2025 | |
| Daiichi Sankyo INC. | $102.71 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $93.82 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $84.32 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.00 | 2022-2025 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.60 | 2023-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.34 | 2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $76.06 | 2024 | Quviviq |
| Electromed, INC. | $72.12 | 2025 | Smartvest |
| Neurocrine Biosciences, INC. | $55.62 | 2024-2025 | Ingrezza |
| Ucb, INC. | $50.84 | 2024 | Briviact |
| Sanofi Pasteur INC. | $44.33 | 2023 | |
| Phadia US INC. | $38.38 | 2024 | Immunocap |
| Abiomed | $38.31 | 2024 | Impella |
| Tandem Diabetes Care, INC. | $29.59 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Verona Pharma, INC. | $25.20 | 2025 | Ohtuvayre |
| Medtronic, INC. | $23.78 | 2024 | Venaseal |
| Boston Scientific Corporation | $20.39 | 2022 | |
| Cequr Corporation | $19.24 | 2024 | Cequr Simplicity |
| Phathom Pharmaceuticals, INC. | $18.78 | 2025 | Voquezna |
| Axonics, INC. | $18.69 | 2023 | Axonics |
| Amgen INC. | $17.63 | 2022 | |
| Baxter Healthcare | $16.54 | 2022 | |
| Merck Sharp & Dohme LLC | $15.26 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $14.93 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $14.61 | 2023 | |
| Alkermes, INC. | $14.04 | 2023 | Vivitrol |
| Abbott Laboratories | $13.71 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.